Table 4. Hallmarks related oncogenic functional connectivity map (pathway based) statistics.
| Name of Pathway | Network statistics |
||||||
|---|---|---|---|---|---|---|---|
| EVGS | SPS | TPI | GIM | ANG | MET | CDR | |
| Actin cytoskeletal regulation | N-11, E-14 | ||||||
| Adherens junction | N-4, E-5 | N-12, E-19 | N-4, E-2 | N-13, E-21 | |||
| Alpha6 Beta4 mediated signaling | N-15, E-32 | N-8, E-12 | N-4, E-4 | ||||
| Androgen receptor mediated signaling | N-4, E-5 | N-16, E-35 | N-11, E-19 | N-6, E-9 | N-13, E-30 | ||
| AP-1 transcription factor associated signaling | N-10, E-15 | N-21, E-55 | |||||
| ATM dependent DNA damage response | N-3, E-2 | ||||||
| Bladder cancer associated pathogenesis | N-10, E-9 | ||||||
| CDC42 mediated signaling | N-21, E-55 | ||||||
| Chronic myeloid leukemia pathogenesis | N-6, E-5 | N-12, E-14 | N-7, E-8 | N-15, E-22 | N-9, E-11 | ||
| Class I PI3K mediated signaling | N-48, E-110 | N-13, E-20 | N-20, E-27 | ||||
| Colorectal cancer pathogenesis | N-5, E-7 | N-17, E-29 | N-8, E-13 | N-12, E-18 | N-4, E-3 | N-10, E-14 | |
| DNA damage response | N-14, E-17 | N-9, E-12 | |||||
| EGFR mediated signaling | N-19, E-44 | N-12, E-14 | |||||
| Endometrial cancer associated pathogenesis | N-9, E-8 | ||||||
| ERBB mediated signaling | N-13, E-21 | N-9, E-16 | N-4, E-4 | ||||
| Focal Adhesion | N-16, E-32 | N-10, E-20 | N-7, E-7 | N-14, E-27 | N-5, E-6 | ||
| Glioma associated pathogenesis | N-9, E-9 | N-8, E-12 | N-14, E-27 | N-6, E-5 | N-14, E-19 | N-6, E-7 | |
| IGF1 mediated signaling | N-46, E-134 | ||||||
| IFN-gamma signaling | N-26, E-63 | ||||||
| IL-2 mediated signaling | N-15, E-24 | N-9, E-11 | |||||
| IL-3 mediated signaling | N-19, E-40 | ||||||
| IL-5 mediated signaling | N-14, E-23 | ||||||
| IL-6 mediated signaling | N-17, E-39 | N-7, E-7 | |||||
| IL-7 mediated signaling | N-7, E-7 | ||||||
| IL-11 mediated signaling | N-8, E-9 | ||||||
| Insulin mediated signaling | N-48, E-110 | N-20, E-27 | |||||
| Integrin-linked kinase associated signaling | N-21, E-55 | ||||||
| JAK-STAT signaling | N-6, E-5 | ||||||
| Kit receptor associated signaling | N-5, E-4 | N-4, E-3 | |||||
| Leptin signaling | N-11, E-25 | N-5, E-5 | |||||
| MAPK signaling | N-5, E-3 | N-13, E-15 | N-4, E-3 | ||||
| Melanoma pathogenesis | N-9, E-8 | N-13, E-15 | N-7, E-5 | ||||
| Microtubule cytoskeletal regulation | N-5, E-6 | ||||||
| Neurotrophin signaling | N-4, E-3 | ||||||
| Non small lung cancer associated pathogenesis | N-10, E-11 | ||||||
| Oncostatin M signaling | N-12, E-19 | N-10, E-9 | N-4, E-3 | ||||
| Pancreatic cancer pathogenesis | N-5, E-7 | N-11, E-13 | N-8, E-10 | N-13, E-13 | N-6, E-5 | N-20, E-30 | N-7, E-8 |
| PAR1 mediated thrombin signaling | N-10, E-15 | ||||||
| PDGFR-beta associated signaling | N-23, E-63 | N-13, E-20 | |||||
| Prolactin signaling | N-10, E-17 | N-11, E-12 | N-14, E-21 | ||||
| Senescence & autophagy associated signaling | N-5, E-3 | N-10, E-11 | N-5, E-4 | ||||
| TGF beta associated signaling | N-4, E-5 | N-20, E-42 | N-11, E-21 | N-13, E-19 | |||
| TRAIL signaling | N-23, E-29 | ||||||
| VEGF signaling | N-4, E-4 | ||||||
Abbreviations: EVGS-Evasion of growth suppression, SPS-sustaining proliferative signaling, TPI-Tumor promoting inflammation, GIM-Genomic instability & mutation, ANG-Angiogenesis, MET-Metastasis, CDR-Cell death resistance, N- Node, number of protein present in the corresponding network, E-Edge, number of binary (physical) interactions between the proteins present in the corresponding network